Lunai Bioworks Inc.

What they do

Lunai Bioworks operates through two subsidiaries: Renovaro Biosciences, which develops allogeneic cell and gene therapies for cancer and infectious diseases, and BioSymetrics, an AI platform for biomarker discovery and drug development. The company has no approved products and has never generated sales revenue, relying on securities sales and debt financing to fund operations.

Revenue drivers

• No product revenue — The company has never generated sales revenue; all reported revenue figures are zero in recent years (e.g., 2024 and 2025 annual revenue $0).
• GEDi Cube (bankrupt) — GediCube B.V., acquired in 2024, filed for bankruptcy in September 2025 and was deconsolidated; no revenue contribution expected.
• BioSymetrics AI platform — Acquired April 2025; commercial potential remains unproven, with no reported revenue from this segment.

Recent performance

For the fiscal year ended June 30, 2025, the company reported net loss of $178.0 million, with diluted EPS of $-1.08, and operating cash outflow of $7.9 million. As of March 31, 2026, cash and equivalents were $3.2 million, total assets $9.9 million, total liabilities $19.4 million, and shareholder equity was negative $9.6 million. The company had an accumulated deficit of $510.5 million as of June 30, 2025, and reported quarterly revenue of $20,942 in Q1 2026, which is immaterial relative to expenses.

Strategy

Management states the primary focus is developing the GEDi Cube and BioSymetrics technologies, with a shift toward AI-driven precision medicine. The company intends to advance Renovaro Biosciences' allogeneic cell therapy platform, including RENB-DC11 for pancreatic tumors, which has completed pre-IND phase. They are seeking non-dilutive grant funding and have restructured debt to provide operational flexibility, though the GEDi Cube bankruptcy has reduced the subsidiary count.

Risks

• Going concern — Substantial doubt exists about the ability to continue as a going concern for one year after the financial statement date, given limited cash and ongoing losses.
• Funding needs — Requires substantial additional financing; failure to obtain capital could force delay or termination of product development.
• Never profitable — No approved products or revenue; expects to continue incurring losses and may never be profitable.
• Bankruptcy of subsidiary — GediCube B.V. filed for bankruptcy in September 2025, resulting in impairment and deconsolidation, indicating operational and financial strain.

Outlook

Management expects to continue incurring losses and requires significant funding to support operations and product development. They plan to pursue non-dilutive grants and may need to raise additional capital, which could cause dilution. The company remains pre-clinical with no near-term revenue visibility, and the bankruptcy of GediCube reduces its operational scope.